您好, 歡迎來到化工儀器網(wǎng),! 登錄| 免費注冊| 產(chǎn)品展廳| 收藏商鋪|
當前位置:深圳遠揚化學技術有限公司>>技術文章>>托法替尼申報用雜質(zhì)
枸櫞酸托法替尼背景及作用機理:
枸櫞酸托法替尼是由美國輝瑞制藥公司開發(fā)一種治療類風濕關節(jié)炎藥物,,商品名Xeljanz,,用于對氨甲喋呤治療應答不充分或不耐受的中至重度活動性類風濕關節(jié)炎(RA)成人患者,。本產(chǎn)品是一種Janus激酶抑制劑,,每日服用兩次,。
2012年11月6日,,美國食品藥品管理局(FDA)和輝瑞公司聯(lián)合宣布,,枸櫞酸托法替尼獲準用于對氨甲喋呤治療應答不充分或不耐受的中至重度活動性類風濕關節(jié)炎(RA)成人患者,。
Xeljanz可作為單一治療或與氨甲喋呤或其他非生物疾病緩解性抗風濕藥物(DMARD)聯(lián)合使用。該藥不應與生物性DMARD或強免疫抑制劑(如硫唑嘌呤和環(huán)孢菌素)聯(lián)合使用,。經(jīng)核準的Xeljanz劑量為每日2次,,每次5mg,。
深圳遠揚化學可提供托法替尼申報所用全套雜質(zhì), 隨貨附CoA證書,,HNMR,,MS,HPLC圖譜,,純度符合申報要求,,托法替尼雜質(zhì)為我司優(yōu)勢雜質(zhì),長期備有庫存,,發(fā)貨快,。如需托法替尼雜質(zhì)相關詳細信息,歡迎我司業(yè)務人員獲取~
除自主品牌雜質(zhì)對照品外,,我司還代理英國NIBSC標準品,,美國劍橋CIL同位素標準品,美國NIST標準物質(zhì),,歐洲標準局IRMM標準物質(zhì),,加拿大TRC標準品,TLC標準品,,MOLCAN標準品,,NRC標準品等,歡迎洽談,。
附:托法替尼申報用雜質(zhì)列表:
Tofacitinib | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 1 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-1H-indol-4-amine |
Tofacitinib Impurity 2 | 2-chloro-N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
Tofacitinib Impurity 3 | 3-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 4 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 5 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxoprop* |
Tofacitinib Impurity 6 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoic acid |
Tofacitinib Impurity 7 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
Tofacitinib Impurity 8 | N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride |
Tofacitinib Impurity 9 | 3-((3R,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile compound with 3-((3S,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (1:1) |
Tofacitinib Impurity 10 | 3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 11 | (3R,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
Tofacitinib Impurity 12 | (3S,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
Tofacitinib Impurity 13 | (3S,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
Tofacitinib Impurity 14 | (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
Tofacitinib Impurity 15 | 3-((3R,4R)-3-(7H-[4,7'-bipyrrolo[2,3-d]pyrimidin]-4'-yl(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 16 | (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carbaldehyde |
Tofacitinib Impurity 17 | N-methyl-N-((3R,4R)-4-methyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
Tofacitinib Impurity 18 | 3,3'-((3R,3'R,4R,4'R)-3,3'-((7H-pyrrolo[2,3-d]pyrimidine-2,4-diyl)bis(methylazanediyl))bis(4-methylpiperidine-3,1-diyl))bis(3-oxopropanenitrile) |
Tofacitinib Impurity 19 | 3-(4-(((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 20 | 3-((3R,4R)-3-((6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile |
Tofacitinib Impurity 21 | N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide |
Tofacitinib Impurity 22 | (3R,4R)-1-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethylpiperidin-3-amine hydrochloride |
Tofacitinib Impurity 23 | (3R,4R)-N,4-dimethyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-amine |
Tofacitinib Impurity 24 | N-((3R,4R)-1,4-dimethylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride |
Tofacitinib Impurity 25 | 1-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone |
Tofacitinib Impurity 26 | N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine compound with N-((3S,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1:1) |
Tofacitinib Impurity 27 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實性,、準確性和合法性由相關企業(yè)負責,,化工儀器網(wǎng)對此不承擔任何保證責任。
溫馨提示:為規(guī)避購買風險,,建議您在購買產(chǎn)品前務必確認供應商資質(zhì)及產(chǎn)品質(zhì)量,。